Search
Filter Results
Displaying 411–420 of 470 results for “fut credit Visitez le site Buyfc26coins.com Support incomparable pour mes FC 26 coins.K5QU”
-
DiseaseOften diagnosed in childhood or adolescence, BBS is an inherited disease causing progressive loss of night and peripheral vision from retinitis pigmentosa. BBS can also cause a number of other symptoms and problems including: obesity, extra fingers and toes, kidney disease, and developmental disabilities. Symptoms vary from person to person.
-
DiseaseAchromatopsia is an inherited retinal disease causing loss of visual acuity as well as central and color vision and vision in lighted conditions.
-
Jan 17, 2018
Clinical Trial to Launch for System Combining Optogenetics and Eyewear
Research NewsThe French biotech GenSight Biologics has received regulatory authorization in the UK to launch the PIONEER Phase 1 \ 2 clinical trial for its GS030 system — a light-sensing gene therapy (optogenetics) coupled with eyewear, which enhances visual stimulation.
-
Jan 9, 2018
Top Retinal Research Advances for 2017
Research NewsAn exciting year in fighting blindness.
-
Dec 20, 2017
History Is Made: FDA Approves Spark's Vision-Restoring Gene Therapy
Research NewsKnown as LUXTURNA™ (voretigene neparvovec), the gene therapy restored vision in a clinical trial for people between the ages of 4 and 44 with Leber congenital amaurosis (LCA) caused by mutations in the gene RPE65.
-
Dec 17, 2017
Beacon Stories“I try not to get my hopes up too much, but I never lose hope; I’m determined. I just want to see my son’s face, see him get married, & see my grandchildren. I encourage everyone with a retinal disease to get a genetic test & to never ever give up hope.“
-
Oct 12, 2017
Research NewsInvestigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
-
Oct 9, 2017
Beacon StoriesJoe Caruso, founder of FOCUS Wine Foundation, knows life both with and without the ability to see. His first memory is sitting in the waiting room with his mother at the Scheie Eye Institute in Philadelphia.
-
Sep 27, 2017
The Foundation's Investments Are Filling the Pipeline for Vision-Saving Therapies
Research NewsIn addition to funding promising biotech start-ups, the Foundation Fighting Blindness has played a critical role in developing research talent.
-
Sep 20, 2017
Heather Presnar’s Story: Living with Stargardt Disease
Beacon StoriesWhen you’re the catcher, the ball always comes to you. Heather Presnar wouldn’t have had it any other way.